[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100491764":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":19,"responsibleParty":41,"collaborators":7,"id":43,"slug":7,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":7,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":7,"studyType":55,"phases":7,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"REGENXBIO Inc.","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DIAGNOSTIC_TEST","AAV8 DetectCDx","An in vitro diagnostic assay to detect antibodies to AAV8 in human serum specimens.",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Patient Advocacy","CONTACT","(833) 711-0349","Duchenne@regenxbio.com",[20],{"facility":21,"status":22,"city":23,"state":24,"zip":25,"country":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Rare Disease Research","RECRUITING","Atlanta","Georgia","30329","United States",{"type":28,"coordinates":29},"Point",[30,31],-84.38798,33.749,{"lat":31,"lon":30},[34,38],{"name":35,"role":16,"phone":36,"phoneExt":7,"email":37},"Maureen Ikpeoha","470-666-1884","maureen.ikpeoha@rarediseaseresearch.com",{"name":39,"role":40,"phone":7,"phoneExt":7,"email":7},"Han Phan, MD","PRINCIPAL_INVESTIGATOR",{"type":42,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100491764",false,"NCT05683379","AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD","Anti-AAV8 Antibody Assessment Study of Males With Duchenne Muscular Dystrophy Aged 0 to \u003C25 Years","Inclusion Criteria:\n\n* Males at least 0 to \\\u003C25 years of age\n* Diagnosis of DMD\n* Provision of signed and dated informed consent form (ICF) and assent as required per local regulations or requirements\n\nExclusion Criteria:\n\n* Prior participation in a gene therapy trial OR recipient of a gene therapy drug\n* Other inclusion\u002Fexclusion criteria apply","MALE","0 Years","25 Years",{"count":53,"type":54},200,"ESTIMATED","OBSERVATIONAL","This is an observational screening study to evaluate the prevalence of anti-adeno-associated serotype 8 (AAV8) antibodies in participants with Duchenne muscular dystrophy (DMD).",[58],"Duchenne Muscular Dystrophy",[60,58,61],"DMD","Duchenne","2026-06-25",{"date":64,"type":65},"2026-06-30","ACTUAL",{"date":67,"type":65},"2022-12-20",{"date":69,"type":54},"2026-09",{"name":5,"class":6},1]